170 related articles for article (PubMed ID: 31727629)
21. Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist.
Gu A; Torres-Coronado M; Tran CA; Vu H; Epps EW; Chung J; Gonzalez N; Blanchard S; DiGiusto DL
Hum Gene Ther Methods; 2014 Aug; 25(4):221-31. PubMed ID: 25003230
[TBL] [Abstract][Full Text] [Related]
22. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
24. Acute exercise mobilizes hematopoietic stem and progenitor cells and alters the mesenchymal stromal cell secretome.
Emmons R; Niemiro GM; Owolabi O; De Lisio M
J Appl Physiol (1985); 2016 Mar; 120(6):624-32. PubMed ID: 26744505
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
27. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
28. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
29. Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy.
Gautam A; Beiss V; Wang C; Wang L; Steinmetz NF
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575893
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
[TBL] [Abstract][Full Text] [Related]
31. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
32. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques.
Barese CN; Felizardo TC; Sellers SE; Keyvanfar K; Di Stasi A; Metzger ME; Krouse AE; Donahue RE; Spencer DM; Dunbar CE
Stem Cells; 2015 Jan; 33(1):91-100. PubMed ID: 25330775
[TBL] [Abstract][Full Text] [Related]
33. Maturation of hematopoietic stem cells from prehematopoietic stem cells is accompanied by up-regulation of PD-L1.
Tober J; Maijenburg MMW; Li Y; Gao L; Hadland BK; Gao P; Minoura K; Bernstein ID; Tan K; Speck NA
J Exp Med; 2018 Feb; 215(2):645-659. PubMed ID: 29282253
[TBL] [Abstract][Full Text] [Related]
34. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Clay TM; Custer MC; Spiess PJ; Nishimura MI
Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
[TBL] [Abstract][Full Text] [Related]
35. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
36. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
[TBL] [Abstract][Full Text] [Related]
38. Glioma tropism of lentivirally transduced hematopoietic progenitor cells.
Tabatabai G; Hasenbach K; Herrmann C; Maurer G; Möhle R; Marini P; Grez M; Wick W; Weller M
Int J Oncol; 2010 Jun; 36(6):1409-17. PubMed ID: 20428764
[TBL] [Abstract][Full Text] [Related]
39. Assessing the Impact of Cyclosporin A on Lentiviral Transduction and Preservation of Human Hematopoietic Stem Cells in Clinically Relevant
Petrillo C; Calabria A; Piras F; Capotondo A; Spinozzi G; Cuccovillo I; Benedicenti F; Naldini L; Montini E; Biffi A; Gentner B; Kajaste-Rudnitski A
Hum Gene Ther; 2019 Sep; 30(9):1133-1146. PubMed ID: 31037976
[TBL] [Abstract][Full Text] [Related]
40. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD
Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
